Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C.
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...
Beam Therapeutics has raked in $135 million in its second formal financing round. Since launching in May 2018, the biotech firm has raised over $220 million to develop therapies that use base-editing ...
About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this ...
On Monday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for ...
Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), and Beam Therapeutics (NASDAQ:BEAM) were among clinical-stage biotechs to receive Overweight ratings at Cantor Fitzgerald as the ...
Biotech stocks continued to surge on Wednesday after two scientists responsible for gene-editing tool CRISPR received this year’s Nobel Prize for Chemistry. CRISPR-powered stocks Intellia Therapeutics ...
The first patient has been dosed with a base editor — the latest genome-editing technology to enter the clinic — and other trials are set to start soon. These therapeutics are designed to permanently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback